Featured

South African Ebola diagnostic response in Sierra Leone: A modular high biosafety field laboratory

The SA FEDL operated in the Western Area of Sierra Leone, which remained a "hotspot" of the EVD epidemic for months. The FEDL was the only diagnostic capacity available to respond to the overwhelming demand for rapid EVD laboratory diagnosis for several weeks in the initial stages of the EVD crisis in the capital of Sierra Leone. Furthermore, the NICD set out to establish local capacity amongst Sierra Leonean nationals in all aspects of the FEDL functions from the outset. This led to the successful hand-over of the FEDL to the Sierra Leone Ministry of Health and Sanitation in March 2015.

Read more: South African Ebola diagnostic response in Sierra Leone: A modular high biosafety field laboratory

EDCTP ENDORSE Train the Trainers (T-t-T) Phase 1 Implemented Successfully

EDCTP ENDORSE Train-the-Trainer (T-t-T) course Phase 1 has been implemented with great success at the city of Gulu in Northern Uganda. Counting on the adherence of the 9 Associate Hospitals involved in the Project, the event took place at St. Mary’s Hospital Lacor premises between 24th to 29th of April 2017. The T-t-T Phase 1 reached the objectives proposed in the work plan of the ENDORSE Project thanks to its’ devoted team of trainers and fully engaged healthcare officer participants. It provided important opportunity for exchange of knowledge among local and international partners and provided practical sessions that will help healthcare officers of the Associate Hospitals to take immediate action when it is needed. Some of the topics covered were: Biological agents, Viral Hemorrhagic Fever, Personal Protective Equipment, Public Health Measures for Epidemics, Principles of decontamination, Waste management, Incident Management, among others.

In order to achieve the capacity building objectives, EDCTP ENDORSE has designed and is now testing a sustainable Train the Trainer model that is being implemented via two subsequent training phases.

Read more: EDCTP ENDORSE Train the Trainers (T-t-T) Phase 1 Implemented Successfully

Ebola in Democratic Republic of Congo to Cost $10 Million, WHO Says

A fresh outbreak of Ebola in the Democratic Republic of Congo (DRC) will cost $10 million to fight, and it could take months because victims are in such a remote and disrupted part of the country, the World Health Organization said Thursday.
At least 20 people are sick and three have been killed by the virus, WHO officials said. They are the first case — a 39-year-old man — a person who cared for him and a man who drove him on a motorcycle to get help.
"There are only 20 kilometers (12 miles) of paved roads in this area and virtually no functioning telecommunications," WHO's Dr. Peter Salama told a news conference.
"As of now we do not know the full extent of the outbreak."

 

Read more: Ebola in Democratic Republic of Congo to Cost $10 Million, WHO Says

Infection Control and Biosafety Products Market 2017 Trend Analysis, Growth and Forecast 2022- Market Research Report

The Global Infection Control and Biosafety Products Market to GROW at a CAGR of 4.21% during the period 2017-2021.

Infection Control and Biosafety Products Market Report focuses on the major drivers and restraints for the key players. These Research Report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market.

Read more: Infection Control and Biosafety Products Market 2017 Trend Analysis, Growth and Forecast 2022-...

WHO prepares experimental Ebola vaccine for possible first use in Democratic Republic of Congo

The World Health Organization and outside experts are making arrangements to send an experimental Ebola vaccine to the Democratic Republic of Congo, should officials there say they need it to quell an outbreak there.
The DRC has not yet formally requested the vaccine, and it's unclear if or when it will. The country's drug regulatory agency would also have to authorize emergency use of the vaccine, which is not yet licensed.
"If the question is: Is it going to be used in this particular outbreak? It's not clear yet," said Dr. Seth Berkley, CEO of Gavi, a public-private partnership that provides vaccines to lower income countries.

Read more: WHO prepares experimental Ebola vaccine for possible first use in Democratic Republic of Congo

Primary Contacts

To send feedback, suggestions or register as a member please contact:

African Biological Safety Association

Fairlane House off Mbagathi Road

P.O Box 35749-00200, Nairobi, Kenya

Tel: +254-714283195, +254-020-5256052 | This email address is being protected from spambots. You need JavaScript enabled to view it.